Valuation: StemRIM

Market Cap 1.87TCr 12Cr 11Cr 9.83Cr 8.91Cr 17Cr 1.13TCr 17Cr 118.26Cr 47Cr 592.47Cr 45Cr 44Cr P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 1.17TCr 7.45Cr 6.65Cr 6.15Cr 5.57Cr 10Cr 707.4Cr 11Cr 74Cr 29Cr 370.63Cr 28Cr 27Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.06%
Yield 2024 *
-
Yield 2025 -
07/10 StemRIM Inc. Announces Patent Registration for Stem Cell Gene Therapy Technology SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in USA CI
25/09 StemRIM Inc. Announces Patent Registration In South Korea For Use Of Redasemtide As Additional Therapeutic Indication Of Cartilage Disorders CI
09/09 StemRIM Reports Earnings Results for the Full Year Ended July 31, 2026 CI
22/07 Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders CI
08/07 StemRIM Inc. Announces Patent Registration For Stem Cell Gene Therapy Technology SR-GT1 Aimed At Curative Treatment Of Dystrophic Epidermolysis Bullosa In South Korea CI
17/06 StemRIM Announces Patent Registration for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders CI
16/06 StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic Steatohepatitis CI
16/06 StemRIM to Register Russian Patent of Drug Candidate for Fatty Liver Disease MT
10/06 StemRIM Reports Earnings Results for the Nine Months Ended April 30, 2026 CI
12/05 Stemrim Inc. Announces Progress for Regeneration-Inducing Medicine Redasemtide CI
15/04 StemRIM Finishes Enrollment in Phase 1/2 Redasemtide Study MT
15/04 StemRIM Inc. Announces Completion of Patient Enrollment in Phase 1/2 InvestigatorInitiated Clinical Trial of Redasemtide for Patients with Ischemic Cardiomyopathy CI
11/03 StemRIM Reports Earnings Results for the Half Year Ended January 31, 2026 CI
1 day+2.07%
1 week-9.76%
Current month-12.94%
1 month-16.38%
3 months-50.67%
6 months-52.10%
Current year-43.73%
1 week 141
Extreme 141
163
1 month 141
Extreme 141
185
Current year 141
Extreme 141
368
1 year 141
Extreme 141
368
3 years 141
Extreme 141
735
5 years 141
Extreme 141
1,518
10 years 141
Extreme 141
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 66 01/02/2007
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.07%-9.76%-49.49%-76.77% 5.92Cr
-2.54%+1.31%+55.10%+120.84% 1,13500Cr
-1.42%+3.23%+37.07%+74.26% 64TCr
+0.16%+0.08%+25.14%+97.36% 50TCr
-0.31%+3.09%+43.92%+64.55% 38TCr
-1.34%-0.47%+66.63%+40.56% 36TCr
-0.68%+2.65%+22.46%+51.48% 29TCr
-1.20%+3.04%+2.62%+26.97% 27TCr
-1.79%+1.57%+49.97%+60.87% 24TCr
-0.73%-0.10%+29.24%+101.19% 19TCr
Average -0.39%+0.98%+28.27%+56.13% 40.04TCr
Weighted average by Cap. -0.26%+2.66%+40.99%+82.13%

Financials

2024 2025
Net sales - -
Net income -202.2Cr -1.29Cr -1.15Cr -1.06Cr -96.4L -1.8Cr -122.41Cr -1.83Cr -13Cr -5.07Cr -64Cr -4.84Cr -4.74Cr -192.9Cr -1.23Cr -1.1Cr -1.01Cr -91.97L -1.72Cr -116.78Cr -1.75Cr -12Cr -4.83Cr -61Cr -4.62Cr -4.52Cr
Net Debt -841Cr -5.36Cr -4.79Cr -4.42Cr -4.01Cr -7.5Cr -509.14Cr -7.63Cr -53Cr -21Cr -266.75Cr -20Cr -20Cr -699.4Cr -4.46Cr -3.98Cr -3.68Cr -3.33Cr -6.24Cr -423.41Cr -6.34Cr -44Cr -18Cr -221.84Cr -17Cr -16Cr
Projected Income Statement - Annual - StemRIM
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
23/26/23 JP¥148.00 +2.07% 4,99,800
22/26/22 JP¥145.00 -3.33% 5,74,900
21/26/21 JP¥150.00 -2.60% 7,44,400
20/26/20 JP¥154.00 -3.14% 7,90,700
19/26/19 JP¥159.00 -3.05% 2,22,500
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - StemRIM

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - StemRIM
  1. Stock Market
  2. Stocks
  3. 4599 Stock